scout
|Articles|June 2, 2014

A Phase I Study of the CSF1R Kinase Inhibitor PLX3397 for PVNS

William D. Tap, MD, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).

<<<

Back to the ASCO 2014 conference page

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME